Please use this identifier to cite or link to this item:
Title: Lrg1 promotes metastatic dissemination of melanoma through regulating egfr/stat3 signalling
Authors: Kwan, Yuet Ping
Teo, Melissa Hui Yen
Lim, Jonathan Chee Woei
Tan, Michelle Siying 
Rosellinny, Graciella
Wahli, Walter
Wang, Xiaomeng 
Keywords: EGFR
Leucine-rich ?-2-glycoprotein-1
Issue Date: 30-Jun-2021
Publisher: MDPI AG
Citation: Kwan, Yuet Ping, Teo, Melissa Hui Yen, Lim, Jonathan Chee Woei, Tan, Michelle Siying, Rosellinny, Graciella, Wahli, Walter, Wang, Xiaomeng (2021-06-30). Lrg1 promotes metastatic dissemination of melanoma through regulating egfr/stat3 signalling. Cancers 13 (13) : 3279. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Although less common, melanoma is the deadliest form of skin cancer largely due to its highly metastatic nature. Currently, there are limited treatment options for metastatic melanoma and many of them could cause serious side effects. A better understanding of the molecular mechanisms underlying the complex disease pathophysiology of metastatic melanoma may lead to the identification of novel therapeutic targets and facilitate the development of targeted therapeutics. In this study, we investigated the role of leucine-rich ?-2-glycoprotein 1 (LRG1) in melanoma development and progression. We first established the association between LRG1 and melanoma in both human patient biopsies and mouse melanoma cell lines and revealed a significant induction of LRG1 expression in metastatic melanoma cells. We then showed no change in tumour cell growth, proliferation, and angiogenesis in the absence of the host Lrg1. On the other hand, there was reduced melanoma cell metastasis to the lungs in Lrg1-deficient mice. This observation was supported by the promoting effect of LRG1 in melanoma cell migration, invasion, and adhesion. Mechanistically, LRG1 mediates melanoma cell invasiveness in an EGFR/STAT3-dependent manner. Taken together, our studies provided compelling evidence that LRG1 is required for melanoma metastasis but not growth. Targeting LRG1 may offer an alternative strategy to control malignant melanoma. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Cancers
ISSN: 2072-6694
DOI: 10.3390/cancers13133279
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers13133279.pdf24.57 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons